News Briefs: Genentech Will Voluntarily Withdraw Gavreto’s RET-Mutant Thyroid Cancer Indication

On June 30, Blueprint Medicines Corp. revealed that partner Genentech USA, Inc., a member of the Roche Group, will voluntarily withdraw Gavreto’s (pralsetinib) indication for the treatment of people at least 12 years old with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer who require systemic therapy. The FDA gave the indication accelerated approval on Dec. 1, 2020. Genentech said the decision, which was made in consultation with the FDA, was not due to new safety or efficacy data but rather due to the “feasibility” of conducting the Phase III confirmatory trial required for full approval. Confirmatory studies to convert the other indications of the kinase inhibitor, all of which have accelerated approval, to full approval are ongoing.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
June 8

News Briefs: Amneal Launches Fylnetra, Sixth Neulasta Biosimilar in U.S.

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
May 11

News Briefs: Celltrion Launches Vegzelma, Fourth Avastin Biosimilar in U.S.

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
April 13

News Briefs: J&J, AbbVie Units Will Withdraw Two Imbruvica Indications

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today